arrow_back Back Filing freshness 20-F Q4 FY2025 SEC EDGAR

Anbio Biotechnology

NNNN
$3.61 ▼ -0.07 (-1.90%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
4 Visible periods
3 Metrics
Peer-ranked Benchmarks
Price Chart
66
Health
Good
Bullish
auto_awesome

Analytical Summary

Anbio Biotechnology shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap —
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC —
FCF / Share —
Trailing P/E —
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
67
Returns ↓
88
Cash Quality
10

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 4 years · 4 quarters